Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — Q1 FY2021 Earnings Presentation
13 slides from Cencora's earnings presentation, Feb 4, 2021
Slide 1: Q1 FY2021 Financial Results
Q1 FY2021 Financial Results February 4, 2021
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "ou
Slide 3: United in our responsibility to create healthier futures
AmerisourceBergen is united in our responsibility to create healthier futures. AmerisourceBergen drives innovative partnerships with global manufacturers, providers, and pharmacies to improve product access and efficiency throughout the healthcare supply chain. 3
Slide 4: Overview
Overview Strong Q1 Positioned for long- Fiscal 2021 performance term growth guidance update • 20%+ adjusted • Differentiated suite • Updated fiscal 2021 operating income of solutions for guidance reflects and diluted EPS partners and the first quarter growth1 customers across performance, solid • Si
Slide 5: Q1 FY2021 financial results
Q1 FY2021 financial results Consolidated results GAAP Adjusted (non-GAAP)1 Revenue $52.5B $52.5B % Change (Year-over-Year) 9.7% 9.7% Gross profit $1.5B $1.4B % Change 18.0% 14.8% Operating expenses $905M $810M % Change (6.5)% 8.3% Operating income $547M $617M % Change 107.7% 24.6% Interest expense,
Slide 6: Pharmaceutical Distribution Services segment
Q1 FY2021 financial results Pharmaceutical Distribution Services segment Q1 FY2021 Q1 FY2020 Revenue $50.5B $46.0B Operating income $496M $392M Percentages of revenue Gross profit 2.06% 1.94% Operating expenses 1.08% 1.09% Operating income 0.98% 0.85% ▪ Revenue increase driven by strong specialty pr
Slide 7: Other — Global Commercialization Services & Animal Health
Q1 FY2021 financial results Other — Global Commercialization Services & Animal Health Q1 FY2021 Q1 FY2020 Revenue $2.1B $1.8B Operating income $122M $104M Percentages of revenue Gross profit 18.88% 19.01% Operating expenses 12.95% 13.35% Operating income 5.93% 5.66% ▪ Other includes MWI, World Couri
Slide 8: FY2021 guidance
FY2021 guidance Updates driven by strong performance and solid execution Expectations on an adjusted (non-GAAP) basis1 Revenue High-single digit percent growth Diluted earnings per share $8.40 to $8.60 Operating expense Mid- to high-single digit percent growth Operating income High-single digit perc
Slide 9: Purpose fuels performance
Purpose fuels performance Why we exist We are united in our responsibility to create healthier futures Our key strengths Best customer base Leader in specialty Innovation mindset Corporate stewardship distribution and commercialization Our growth strategies Customer focus Expand on Execution and inn
Slide 10: Appendix
Appendix
Slide 11: Note on non-GAAP financial measures
Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the exhibit to the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 11
Slide 12: Note on non-GAAP financial measures
Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the exhibit to the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 12
Slide 13: Contact
Contact Bennett S. Murphy Senior Vice President Investor Relations bmurphy@amerisourcebergen.com